Tourmaline Bio Inc (NASDAQ:TRML) price on Friday, February 07, fall -4.74% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $14.28.
A look at the stock’s price movement, the close in the last trading session was $14.99, moving within a range at $14.145 and $15.005. Turning to its 52-week performance, $48.31 and $12.12 were the 52-week high and 52-week low respectively. Overall, TRML moved -29.27% over the past month.
Tourmaline Bio Inc’s market cap currently stands at around $366.17 million, with investors looking forward to this quarter’s earnings report slated for in March.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TRML is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
TRML’s current price about -16.37% and -29.99% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 25.36, while 7-day volatility ratio is 6.09% and 5.76% in the 30-day chart. Further, Tourmaline Bio Inc (TRML) has a beta value of 2.34, and an average true range (ATR) of 1.05. Analysts have given the company’s stock an average 52-week price target of $50, forecast between a low of $50 and high of $50. Looking at the price targets, the low is -250.14% off current price level while to achieve the yearly target high, price needs to move -250.14%. Nonetheless, investors will most likely welcome a -250.14% jump to $50 which is the analysts’ median price.
If we refocus on Tourmaline Bio Inc (NASDAQ:TRML), historical trading data shows that trading volumes averaged 0.36 over the past 10 days and 233.10K over the past 3 months. The company’s latest data on shares outstanding shows there are 25.64 million shares.
The 39.16% of Tourmaline Bio Inc’s shares are in the hands of company insiders while institutional holders own 63.58% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.33 million on 2025-01-15, giving us a short ratio of 11.16. The data shows that as of 2025-01-15 short interest in Tourmaline Bio Inc (TRML) stood at 1019.0000000000001 of shares outstanding, with shares short rising to 1.64 million registered in 2024-12-13. Current price change has pushed the stock -29.59% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TRML stock continues to rise going into the next quarter.
